Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 15, 1996Circulation

Spironolactone and its major metabolites inhibited bFGF-induced angiogenesis, endothelial cell proliferation, and chemotaxis in preclinical models.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does spironolactone inhibit angiogenesis in preclinical models?

Population

Preclinical models including rabbit corneal micropocket assay, in vitro capillary endothelial cells, and…

Design

Preclinical

Authors

NKNancy KlauberFBFiona BrowneBABela Anand‐Apte

Discussion

Loading...

Member takes

Overview

May suggest unrecognized antiangiogenic effects; hypothesis-generating and should not yet change practice.

Structured PICO

Does spironolactone inhibit angiogenesis in preclinical models?

P
Population
Preclinical models including rabbit corneal micropocket assay, in vitro capillary endothelial cells, and chick chorioallantoic membrane
I
Intervention
Spironolactone and its metabolites (6 beta-hydroxy-7 alpha-thiomethyl spironolactone and canrenoic acid)
O
Outcome
Inhibition of angiogenesis (area of angiogenesis, capillary endothelial cell proliferation, and chemotaxis)surrogate

Spironolactone exhibits novel antiangiogenic properties in preclinical models, independent of its known antimineralocorticoid effects.

Cite This Study

Klauber et al. (1996) studied this question.

synapsesocial.com/papers/6a21697e5c0c8498e257ffcehttps://doi.org/10.1161/01.cir.94.10.2566
View Full Paper
Ask AI
Bookmark
Share